Business
CURE Pharma Could Take Over Where Zynerba Fell Short -- CFN Media
CURE Pharma Could Take Over Where Zynerba Fell Short -- CFN Media.
About this update from Avenir Wellness Solutions Inc.
[{"type":"text","content":"\n \n \n CURE Pharma Could Take Over Where Zynerba Fell Short -- CFN Media\n \n \nCURE Pharma Could Take Over Where Zynerba Fell Short -- CFN Media\n \n SEATTLE, WA--(Marketwired - Aug 11, 2017) - CFN Media Group (\"CannabisFN\"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing CURE Pharmaceutical Holding Corp.(OTCQB: CURR) and its development of an oral thin film drug delivery solution that could succeed where Zynerba Pharmaceuticals' cannabidiol gel system recently failed to meet clinical endpoints.\n What's Different?\n CURE Pharma is a relatively new entrant into the pharmaceutical cannabinoid market. In May, the company announced that it had begun researching and developing proprietary formulas consisting of various cannabinoids and terpene profiles integrated into its advanced oral thin film technology, known as CureFilm™. Management has since focused on forming partnerships and collaborations with top healthcare and cannabis industry organizations around the world.\n \"Our goal is to bring new cannabinoid molecules to market through the FDA regulatory process, while utilizing our company's proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options,\" said CURE Pharma CEO Rob Davidson.\n CureFilm™ leverages a micro-encapsulation process that protects active ingredients to enable higher dosing with better flavor masking. Unlike competing delivery systems, the technology can load multiple active pharmaceutical ingredients -- or APIs -- onto a single strip. The plan is to leverage the so-called entourage effect of cannabinoids while providing better bioavailability than many competing technologies to maximize safety and efficacy.\n Advancing Studies\n CURE Pharma has developed several partnerships with leading cannabinoid researchers to advance its clinical programs. These research agreements could help accelerate the company's time-to-market by partnering with pharmaceutical companies developing cannabinoid-based therapies and then applying its proprietary CureFilm™ delivery system to increase the safety and efficacy profile of the drugs as they move through regulatory approvals.\n In mid-July, the company ...